Book Value per Share: BeOne Medicines (BGNE)

Public company logo of BeiGene Ltd. (BGNE)

BeiGene, Ltd. (BGNE) is scaling its expansion through proprietary sales networks in China and the US. Stable demand for patented targeted therapy creates financial momentum, while robotic bio-screening accelerates the discovery of formulas. The book value per share confirms capital strengthening amid Fed policy, while the value of 45.35 records the metric level, demonstrating the overall reliability of the assets.

BeiGene Ltd. (BGNE) - Accounting Value per Share from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for beigene.com (BGNE)

- price and consensus price forecast:
Price Chart BeOne Medicines|BGNE - Broker Consensus Forecast
- market capitalization data:
Market Capitalization BeiGene, Ltd.|BGNE - Total Enterprise Value
- book capitalization data:
Book Value per Share BeiGene|BGNE - Company Net Assets|Market Capitalization to Book Value Ratio beigene.com|BGNE - Company Total Assets
- debt and liquidity data:
Debt to Equity BeiGene, Ltd.|BGNE - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital BeiGene|BGNE - Company Total Debt|Debts to Book Capitalization BeiGene, Ltd.
Analysis of all company metrics:BeOne Medicines, BGNE
Manufactured product of beigene.com

Book value per share reflects the actual liquidation foundation of the business, measuring the value of net assets minus all liabilities regardless of market fluctuations. The upward trend in book value per share confirms the capitalization of assets, which is critically important for BeiGene, Ltd. (BGNE) as it scales its global oncology portfolio and expands its network of international clinical trials.

Competitor analysis for BeiGene, Ltd.

BeiGene Corp (ONC) - Net Assets per Single Share|HALO - Equity per Share|Book Value per Share RVMD|ascentage.com (AAPG) - Net Asset Value per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|Book Value per Share Radiopharm Theranostics Limited (RADX)|Net Assets per Single Share artivabio.com (ARTV)|ANL: Book Value per Share|Net Asset Value per Share Veru Inc VERU|Book Value per Share TPST (Tempest Tx)|XLO - Net Assets per Share|Book Value per Share RENB (renovarobio.com)|Mural Oncology (MURA) - Book Value of One Share|Book Value per Share KAPA (Kairos Pharma Limited)|Net Asset Value per Share OKUR|Net Assets per Single Share CytoMed Therapeutics GDTC|Equity per Share curis.com (CRIS)|APLM: Book Value per Share|THAR - Net Asset Value per Share|Accounting Value per Share Advanced Biomed Corp (ADVB)|GNPX: Accounting Value of a Share|calidibio.com (CLDI) - Net Assets per Single Share|Net Assets per Single Share Sunshine Biopharma Inc.|Xenetic Biosciences Inc. (XBIO) - Accounting Value per Share|Book Price of a Share salariuspharma.com|Book Value per Share Purple Biotech Ltd. PPBT|Equity per Share aoncology.com AONC|Accounting Value per Share CKPT|Net Assets per Share elevationoncology.com ELEV|ICAD - Book Value per Share|IKNA - Net Assets per Single Share|Book Value per Share NTBL (Notable Labs)|VIRX (Viracta Therapeutics, Inc.) - Book Value of One Share|Net Assets per Single Share MorphoSys Corp (MOR)|Equity per Share NAYA Biosciences Corp|Ascentage Pharma Group - Book Value per Share